Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer
| Autor: | Efraim Idelevich, Sofia Man, Nana Ben Zvi, Michael Dinerman, Noa Ben Baruch, Adi Shani, Rivka L. Katsenelson, Natalie Karminsky, Haim Biran |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms Time Factors Anemia Leucovorin Phases of clinical research Bone Neoplasms Adenocarcinoma Neutropenia Gastroenterology Drug Administration Schedule Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Uracil Peritoneal Neoplasms Aged Epirubicin Tegafur Cisplatin Dose-Response Relationship Drug business.industry Liver Neoplasms Cancer Hematology General Medicine Middle Aged medicine.disease Survival Analysis Confidence interval Treatment Outcome Tolerability Lymphatic Metastasis Female business Follow-Up Studies medicine.drug |
| Zdroj: | Acta Oncologica. 46:324-329 |
| ISSN: | 1651-226X 0284-186X |
| DOI: | 10.1080/02841860600871079 |
| Popis: | More than two-thirds of patients with gastric cancer present with metastatic disease and their curative options are limited. This phase II study assessed the efficacy and tolerability of cisplatin, epirubicin, tegafur-uracil (UFT) and leucovorin in patients with metastatic gastric cancer (MGC). Thirty-nine patients with previously untreated metastatic or unresectable gastric cancer received intravenous cisplatin 60 mg/m2 and epirubicin 50 mg/m2 on day 1 of a 28-day cycle; UFT 300 mg/m2 was administered with oral leucovorin 30 mg/day in divided doses on days 1-22, followed by a 7-day rest. Two patients achieved a complete response, 13 had a partial response (overall response rate 38%; 95% confidence interval [CI] 24-52%) and 16 patients (41%) had stable disease. Median time to progression was 6.5 months (95% CI 5.5-7.5 months); overall survival was 9.5 months (95% CI 8.5-13.5 months). Grade 3/4 neutropenia, anemia, and thrombocytopenia occurred in 20%, 8%, and 3% of patients, respectively; two patients experienced febrile neutropenia. Grade 3 diarrhea occurred in three patients. The combination of cisplatin, epirubicin, UFT, and leucovorin has significant activity and tolerable toxicities in patients with MGC and represents a convenient treatment option for these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|